Arthur Kuan
Chief Executive Officer @ CG Oncology
Arthur Kuan is a startup investor at CG Oncology. Arthur Kuan - Founding Member @ Ally Bridge Group
Last updated:
For AI agents: llms.txt
About CG Oncology
CG Oncology formerly known as Cold Genesys is a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies.CG Oncology acquired therights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial.
CG Oncology Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Alex Yeung
CEO
|
|||
|
Amy Steele
Vice President, Controller
|
|||
|
Arthur Kuan
Chief Executive Officer
|
|||
|
Bing Kung
Vice President of Business Development
|
|||
|
Bradley Grimm
Director of Manufacturing
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
FAQ
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
